These findings suggest that TGFβ may dampen CD8 T cell activity by restraining their provision of IFNγ and that success of combination therapy depends on ensuing IFNγ signaling in multiple non-T cell compartments of the tumor ecosystem. This evidence concerns the gene CD8A and neoplasm.